Cartesian Therapeutics, Inc.
RNAC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001453687
No open-market purchases or sales by Cartesian Therapeutics, Inc. insiders were filed in the last 90 days; 94 institutions reported holding it in 13F filings for Q2 2026, worth $90.4M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Cartesian Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 62 | 1 | 64 | +3 |
| Shares | 3.27M | 407.6K | 6.87M | +4.00M (+139.8%) |
| Value | $88.3M | $11.0M | $110.3M | +$33.1M (+42.8%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Cartesian Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Siren, L.L.C. | 572,236 | $9.22M | 0.46% |
| BlackRock, Inc. | 423,466 | $6.83M | 0.00% |
| Citadel Advisors LLC | 375,767 | $5.76M | 0.01% |
| Great Point Partners LLC | 200,000 | $3.22M | 0.97% |
| Armistice Capital, LLC | 98,565 | $1.59M | 0.04% |
| 683 Capital Management, LLC | 75,431 | $1.22M | 0.12% |
| Schonfeld Strategic Advisors LLC | 50,000 | $797.9K | 0.01% |
| Balyasny Asset Management LLC | 49,497 | $797.9K | 0.00% |
| Ironwood Investment Management LLC | 14,631 | $235.9K | 0.11% |
| Two Sigma Investments, LP | 12,911 | $208.1K | 0.00% |
| Goldman Sachs Group Inc | 11,336 | $182.7K | 0.00% |
| Squarepoint Ops LLC | 10,393 | $167.5K | 0.00% |
| Johnson Financial Group, Inc. | 4,618 | $74.4K | 0.00% |
| Acadian Asset Management LLC | 1,761 | $28.0K | 0.00% |
| Sterling Capital Management LLC | 7 | $113 | 0.00% |
| CoreCap Advisors, LLC | 1 | $0 | 0.00% |
Sold out (13)
Institutions that held Cartesian Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Artal Group S.A. | 304,554 | $8.23M |
| Logos Global Management LP | 90,000 | $2.43M |
| Marshall Wace, LLP | 30,038 | $811.3K |
| Sphera Funds Management Ltd. | 25,070 | $677.1K |
| Renaissance Technologies LLC | 17,052 | $460.6K |
| Cubist Systematic Strategies, LLC | 13,010 | $351.4K |
| MetLife Investment Management | 2,838 | $76.7K |
| Point72 Asia (Singapore) Pte. Ltd. | 1,824 | $49.3K |
| Point72 (DIFC) Ltd | 1,725 | $46.6K |
| Russell Investments Group, Ltd. | 152 | $4.11K |
| National Bank of Canada | 40 | $970 |
| Capital Advisors, Ltd. LLC | 5 | $0 |
| FNY Investment Advisers, LLC | 3 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held Cartesian Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 407,596 | $11.0M |